Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects
- 1 July 2017
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 136, 12-23
Abstract
No abstract availableKeywords
This publication has 115 references indexed in Scilit:
- Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosisCell Death & Disease, 2013
- BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisionsCancer Letters, 2013
- AIF-mediated caspase-independent necroptosis requires ATM and DNA-PK-induced histone H2AX Ser139 phosphorylationCell Death & Disease, 2012
- Bim Inhibits Autophagy by Recruiting Beclin 1 to MicrotubulesMolecular Cell, 2012
- Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 KinaseCell, 2012
- A Unified Model of Mammalian BCL-2 Protein Family Interactions at the MitochondriaMolecular Cell, 2011
- BID regulates AIF-mediated caspase-independent necroptosis by promoting BAX activationCell Death & Differentiation, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- BH3 mimetics to improve cancer therapy; mechanisms and examplesDrug Resistance Updates, 2007
- The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer Cell, 2006